🔎 Trials Near Me

Akèy › Sipwa › Texas › Pharr

Etid klinik pou Sipwa nan Pharr, TX

10 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Pharr (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Ap rekriteFaz 3
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Ap rekriteFaz 3
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Ap rekriteFaz 2
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Ap rekriteFaz 3
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Ap rekriteFaz 3
  • AURORA-1 Clinical Site, Weslaco · 12 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Ap rekriteFaz 3
  • AURORA-2 Clinical Site, Weslaco · 12 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Ap rekriteFaz 2
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Ap rekriteFaz 2
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT07215559

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Ap rekriteFaz 2
  • Texas Valley Clinical Research, Weslaco · 12 mi lwen
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Ap rekriteFaz 3
  • Great Lakes Research Institute - McAllen Research, Pharr
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

Etid Sipwa nan lòt vil

Lòt etid nan Pharr

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.